ArticleJournal of managed care & specialty pharmacy2025

Cost-effectiveness of caplacizumab in immune thrombotic thrombocytopenic purpura in the United States.

Sean D Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.